Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Cocrystal Pharma filed a routine 8-K, no major news.
AI Summary
On January 8, 2025, Cocrystal Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific new material events, financial figures, or significant business updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Cocrystal Pharma, Inc. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- January 8, 2025 (date) — Date of earliest event reported
- 19805 N. Creek Parkway, Bothell, WA 98011 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing for Cocrystal Pharma, Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the Item Information section.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 8, 2025.
Where are Cocrystal Pharma, Inc.'s principal executive offices located?
The principal executive offices are located at 19805 N. Creek Parkway, Bothell, WA 98011.
What is the Commission File Number for Cocrystal Pharma, Inc.?
The Commission File Number for Cocrystal Pharma, Inc. is 001-38418.
What is the IRS Employer Identification Number for Cocrystal Pharma, Inc.?
The IRS Employer Identification Number for Cocrystal Pharma, Inc. is 35-2528215.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-01-08 08:30:38
Filing Documents
- form8-k.htm (8-K) — 33KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001493152-25-001314.txt ( ) — 284KB
- cocp-20250108.xsd (EX-101.SCH) — 3KB
- cocp-20250108_def.xml (EX-101.DEF) — 29KB
- cocp-20250108_lab.xml (EX-101.LAB) — 33KB
- cocp-20250108_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2025 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer